- Home
- MNKD vs IMCR Comparison
MNKD vs IMCR Comparison
Compare MNKD & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- IMCR
- Stock Information
- Founded
- MNKD 1991
- IMCR 2008
- Country
- MNKD United States
- IMCR United Kingdom
- Employees
- MNKD N/A
- IMCR N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNKD Health Care
- IMCR Health Care
- Exchange
- MNKD Nasdaq
- IMCR Nasdaq
- Market Cap
- MNKD 1.5B
- IMCR 1.5B
- IPO Year
- MNKD 2004
- IMCR 2021
- Fundamental
- Price
- MNKD $5.76
- IMCR $29.92
- Analyst Decision
- MNKD Buy
- IMCR Buy
- Analyst Count
- MNKD 6
- IMCR 13
- Target Price
- MNKD $8.92
- IMCR $65.18
- AVG Volume (30 Days)
- MNKD 1.7M
- IMCR 158.6K
- Earning Date
- MNKD 02-26-2025
- IMCR 02-26-2025
- Dividend Yield
- MNKD N/A
- IMCR N/A
- EPS Growth
- MNKD N/A
- IMCR N/A
- EPS
- MNKD 0.08
- IMCR N/A
- Revenue
- MNKD $267,200,000.00
- IMCR $296,312,000.00
- Revenue This Year
- MNKD $44.15
- IMCR $28.89
- Revenue Next Year
- MNKD $19.65
- IMCR $13.00
- P/E Ratio
- MNKD $72.34
- IMCR N/A
- Revenue Growth
- MNKD 51.35
- IMCR 25.09
- 52 Week Low
- MNKD $3.47
- IMCR $27.69
- 52 Week High
- MNKD $7.63
- IMCR $72.56
- Technical
- Relative Strength Index (RSI)
- MNKD 48.03
- IMCR 47.96
- Support Level
- MNKD $5.32
- IMCR $28.41
- Resistance Level
- MNKD $5.65
- IMCR $30.49
- Average True Range (ATR)
- MNKD 0.18
- IMCR 1.47
- MACD
- MNKD 0.03
- IMCR -0.07
- Stochastic Oscillator
- MNKD 81.48
- IMCR 41.03
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.